Olaparib (Lynparza) for metastatic breast cancer in people with a BRCA gene mutation
Urgent opportunity As some of you may know, BCNA provides a
consumer comment to the Pharmaceutical Benefits Advisory Committee (PBAC) in
support of drugs being considered for subsidy on the PBS. Equity of access to
new treatment options is especially important for those with metastatic breast
cancer. Our policy team are…